Oct. 18, 2022 Price forecast | 2 weeks: -2.81% | 1 month: -3.59% | 3 months: 6.26%

IMVT stock forecast

Our latest prediction for Immunovant Inc's stock price was made on the Oct. 18, 2022 when the stock price was at 9.25$.

In the short term (2weeks), IMVT's stock price should underperform the market by -2.81%. During that period the price should oscillate between -12.58% and +5.61%.

In the medium term (3months), IMVT's stock price should outperform the market by 6.26%. During that period the price should oscillate between -33.30% and +19.93%.

Create a solid portfolio with IMVT

Add IMVT to your portfolio and optimize it!

About Immunovant Inc

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.43$ per share.

The book value per share is 3.27$

Immunovant Inc website

Three months stock forecastOct. 18, 2022


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - - - -112M -1.43 - - 116M 3.27 - - -